Waterford, CT, United States of America

Christopher A Lipinski


Average Co-Inventor Count = 1.3

ph-index = 6

Forward Citations = 84(Granted Patents)


Location History:

  • New London, CT (US) (1988)
  • Waterford, CT (US) (1976 - 1991)

Company Filing History:


Years Active: 1976-1991

Loading Chart...
15 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Christopher A. Lipinski

Introduction

Christopher A. Lipinski is a prominent inventor based in Waterford, CT, known for his significant contributions to the field of pharmaceuticals. With a total of 15 patents to his name, Lipinski has made remarkable strides in developing therapeutic agents, particularly for the treatment of diabetic complications.

Latest Patents

Among his latest patents is the invention of spiro-heteroazalones, which serve as aldose reductase inhibitors. These compounds are particularly useful in treating complications arising from diabetes. Additionally, he has developed hydroxyacetic acid derivatives aimed at addressing diabetic conditions. These innovations reflect his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Lipinski is currently associated with Pfizer Corporation, a leading global pharmaceutical company. His work at Pfizer has allowed him to collaborate with some of the brightest minds in the industry, further enhancing his contributions to pharmaceutical research and development.

Collaborations

Some of his notable coworkers include John L. LaMattina and John L. La Mattina, who have also made significant contributions to the field. Their collaborative efforts have fostered an environment of innovation and excellence within the pharmaceutical sector.

Conclusion

Christopher A. Lipinski's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and research continue to pave the way for new treatments that can significantly improve the lives of individuals suffering from diabetes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…